IRADIMED CORP (NASDAQ:IRMD) Institutional Investor Positioning Change

June 20, 2017 - By Hazel Jackson

 IRADIMED CORP (NASDAQ:IRMD) Institutional Investor Positioning Change


IRADIMED CORP (NASDAQ:IRMD) institutional sentiment decreased to 1.11 in 2016 Q4. Its down -0.75, from 1.86 in 2016Q3. The ratio is negative, as 30 active investment managers increased or started new holdings, while 27 sold and trimmed holdings in IRADIMED CORP. The active investment managers in our partner’s database now possess: 2.26 million shares, down from 2.60 million shares in 2016Q3. Also, the number of active investment managers holding IRADIMED CORP in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 12 Increased: 22 New Position: 8.

IRADIMED CORPORATION develops, makes, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The company has market cap of $102.63 million. The Firm operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. It has a 23.09 P/E ratio. The Company’s MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures.

About 6,706 shares traded. Iradimed Corp (NASDAQ:IRMD) has declined 54.40% since June 20, 2016 and is downtrending. It has underperformed by 71.10% the S&P500.

Wall Street await Iradimed Corp (NASDAQ:IRMD) to release earnings on August, 4.

Conestoga Capital Advisors Llc holds 0.37% of its portfolio in Iradimed Corp for 504,600 shares. First Light Asset Management Llc owns 39,355 shares or 0.19% of their US portfolio. Moreover, Ativo Capital Management Llc has 0.18% invested in the company for 68,847 shares. The California-based Globeflex Capital L P has invested 0.12% in the stock. Granite Investment Partners Llc, a California-based fund reported 122,078 shares.#img1#

Since January 1, 0001, it had 1 buying transaction, and 1 insider sale for $47,451 activity.

Iradimed Corp (NASDAQ:IRMD) Ratings Coverage

Ratings analysis reveals 50% of iRadimed’s analysts are positive. Out of 2 Wall Street analysts rating iRadimed, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $25 while the high is $30. The stock’s average target of $27.50 is 203.20% above today’s ($9.07) share price. IRMD was included in 5 notes of analysts from July 30, 2015. The stock of Iradimed Corp (NASDAQ:IRMD) has “Neutral” rating given on Wednesday, October 5 by Roth Capital. TH Capital maintained Iradimed Corp (NASDAQ:IRMD) on Monday, November 2 with “Buy” rating. On Monday, November 2 the stock rating was maintained by Roth Capital with “Buy”. Roth Capital maintained Iradimed Corp (NASDAQ:IRMD) on Monday, April 4 with “Buy” rating. The firm earned “Buy” rating on Thursday, July 30 by TH Capital.

More notable recent Iradimed Corp (NASDAQ:IRMD) news were published by: which released: “iRadimed Corp. (IRMD) CEO Roger Susi on Q3 2016 Results – Earnings Call Transcript” on October 29, 2016, also with their article: “iRadimed Corporation – MRI Compatible IV Infusion Pump Quickly Becoming A …” published on August 16, 2016, published: “IRADIMED CORPORATION Announces Fourth Quarter 2016 Financial Results” on February 06, 2017. More interesting news about Iradimed Corp (NASDAQ:IRMD) were released by: and their article: “iRadimed Poised For Market Domination” published on February 14, 2017 as well as‘s news article titled: “iRadimed: A Niche Medical Device Company With 55%+ Upside Potential” with publication date: August 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.